查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1601264

重組蛋白市場：依產品、服務、最終用戶、功能分類 - 2025-2030 年全球預測

Recombinant Proteins Market by Product (Adhesion Molecules & Receptors, Growth Factors & Chemokines, Immune Response Proteins), Services (Cloning, Expression, Purification), End-User, Function - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年重組蛋白市值為50.5億美元，預計到2024年將達到58億美元，複合年成長率為14.51%，預計到2030年將達到130.4億美元。

重組蛋白是透過重組DNA技術產生的人工蛋白，可在各種宿主系統中表達新蛋白。由於該技術能夠高效地大規模生產高純度蛋白質，因此對於治療、診斷和研究應用極為重要。重組蛋白對於藥物、疫苗和生技藥品的開發以及農業和食品工業中用於改善植物和動物產品至關重要。最終用途包括醫學研究、臨床診斷和生物技術研究。重組蛋白市場受到成長要素的影響，例如反應器設計的進步、研發投資的增加以及需要創新療法的慢性疾病盛行率的上升。這裡蘊藏著豐富的商機，包括對個人化醫療和生物製藥的需求不斷增加，以及基因治療和再生醫學應用的擴大。市場擴張需要開拓新興市場、利用具成本效益的生產技術並建立策略夥伴關係。然而，市場成長面臨高生產成本、複雜的監管環境和智慧財產權問題的挑戰。蛋白質表現和精製所涉及的技術複雜性也構成了障礙。推動創新需要專注於最佳化表達系統、開發用於儲存和運輸的新型穩定技術以及使用基於 CRISPR 的技術來增強蛋白質功能的研究。競爭考慮表明，這個市場競爭激烈，但發展迅速，其特徵是持續的技術進步和向精準醫療的轉變。為了在重組蛋白市場取得長期成功，公司需要跟上技術趨勢和監管變化，並在經營模式中強調永續性和道德考量。

主要市場統計
基準年[2023] 50.5億美元
預測年份 [2024] 58億美元
預測年份 [2030] 130.4億美元
複合年成長率（%） 14.51%

市場動態：揭示快速發展的重組蛋白市場的關鍵市場洞察

供需的動態交互作用正在改變重組蛋白市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 消費者越來越重視個人化醫療和蛋白質療法
    • 老年人和兒童中感染疾病和慢性病的盛行率很高
    • 對生技藥品和生物相似藥蛋白質的需求不斷成長
  • 市場限制因素
    • 對重組蛋白維護相關的高成本和時間消耗的擔憂
  • 市場機會
    • 對生物標記發現的日益關注和對重組蛋白開發的快速投資
    • 重組蛋白在動物繁殖、飼料效率和健康方面的潛力不斷成長
  • 市場挑戰
    • 替代產品的可取得性和生產中的一些問題

波特五力：駕馭重組蛋白市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解重組蛋白市場的外部影響

外部宏觀環境因素在塑造重組蛋白市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解重組蛋白市場的競爭格局

對重組蛋白市場的詳細市場佔有率分析可以對供應商的業績進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣重組蛋白市場供應商績效評估

FPNV定位矩陣是評估重組蛋白市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。四個象限清楚且準確地分類供應商，幫助使用者辨識最能滿足其策略目標的合作夥伴和解決方案。

本報告提供了涵蓋關鍵重點領域的全面市場分析：

1. 市場滲透率：對當前市場環境的詳細回顧，包括行業主要企業的大量資料。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 消費者越來越重視個人化醫療和蛋白質療法
      • 老年人和兒童感染疾病和慢性病盛行率高
      • 生物製藥和生物相似藥蛋白的需求快速成長
    • 抑制因素
      • 重組蛋白成本與維護時間問題
    • 機會
      • 對生物標記發現的更多關注和對重組蛋白開發的投資激增
      • 擴大重組蛋白在動物繁殖、飼料效率和健康方面的潛力
    • 任務
      • 替代產品的可用性和一些生產問題
  • 市場區隔分析
    • 產品：黏附分子和受體在研究中的重要用途
    • 服務：表達服務注重高產量和與目標蛋白質特性的兼容性
    • 最終用戶：重組蛋白在製藥和生物製藥公司的廣泛使用
    • 功能：重組蛋白在藥物發現與開發的潛在需求
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章重組蛋白市場：依產品

  • 黏附分子和受體
  • 生長因子和趨化素
  • 免疫反應蛋白
  • 激酶蛋白
  • 膜蛋白
  • 重組代謝酶
  • 調節蛋白
  • 結構蛋白

第7章重組蛋白市場：依服務分類

  • 複製
  • 表達
  • 精製

第 8 章重組蛋白市場：依最終用戶分類

  • 學術研究所
  • 合約研究組織和契約製造組織
  • 製藥和生物製藥公司

第 9 章重組蛋白市場：按功能

  • 診斷
  • 藥物發現與開發
    • 生物製藥
    • 細胞/基因治療
    • 疫苗

第10章美洲重組蛋白市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太重組蛋白市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲重組蛋白市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • iTolerance 與 Northway Biotech 簽署融合蛋白生產協議
    • Biovian 在芬蘭製造工廠投資超過 5,000 萬歐元
    • 富通生命科學公司收購 International 照護現場
    • Curia 利用 CHOZN 平台擴展細胞株開發服務
    • Future Fields 融資 1,120 萬美元，擴大果蠅重組蛋白生產規模
    • 默克生物開發中心擴建，法國馬蒂利亞克
    • Shenandoah Biotechnology 宣布擴大根據 cGMP 實踐生產的 CTGrade 重組蛋白系列
    • FUJIFILM收購領先的重組蛋白製造商 Shenandoah Biotechnology
    • Thermo Fisher Scientific 完成對 Peprotech 的收購，進軍重組蛋白領域

公司名單

  • Takara Bio Inc.
  • GeoVax Labs, Inc.
  • Takeda Pharmaceutical Company Limited
  • LenioBio GmbH
  • Sino Biological, Inc.
  • Sanofi SA
  • Bio-Rad Laboratories, Inc.
  • R&D Systems, Inc. by Bio-Techne Corporation
  • Proteos, Inc.
  • BPS Bioscience, Inc.
  • Proteintech Group, Inc.
  • BioLegend, Inc. by PerkinElmer, Inc.
  • Thermo Fisher Scientific, Inc.
  • Miltenyi Biotec BV & Co. KG
  • Fortis Life Sciences LLC
  • Sartorius AG
  • Bristol-Myers Squibb Company
  • Creative BioMart Inc.
  • Biogen Inc.
  • Abnova Corporation
  • Hzymes Biotech
  • Merck KGaA
  • Novartis AG
  • Agilent Technologies, Inc.
  • Lonza Group AG
  • SK bioscience
  • Eli Lilly and Company
  • Johnson & Johnson Services, Inc.
  • Bhat Bio-tech India Private Limited
  • GenScript Biotech Corporation
  • Marin Biologic Laboratories, Inc.
  • Meridian Bioscience, Inc. by SD Biosensor Inc.
  • ProMab Biotechnologies, Inc.
  • Abcam PLC
  • Laurus Labs Limited
  • Biologics International Corp
  • Croyez Bioscience Co., Ltd.
  • Enzo Life Sciences, Inc.
  • Selvita SA
Product Code: MRR-501246437434

The Recombinant Proteins Market was valued at USD 5.05 billion in 2023, expected to reach USD 5.80 billion in 2024, and is projected to grow at a CAGR of 14.51%, to USD 13.04 billion by 2030.

Recombinant proteins are engineered proteins that are generated through recombinant DNA technology, enabling the expression of novel proteins in various host systems. This technology is pivotal for therapeutic, diagnostic, and research applications due to its efficiency in producing proteins at a large scale and with high purity. Recombinant proteins are essential in pharmaceuticals for the development of drugs, vaccines, and biologics, as well as in agriculture and food industries for improving plant and animal products. The end-use scope spans medical research, clinical diagnostics, and biotechnological research. The market for recombinant proteins is influenced by growth factors like advancements in bioreactor design, increasing R&D investment, and a rising prevalence of chronic diseases necessitating innovative therapeutics. Opportunities abound in personalized medicine and the growing demand for biopharmaceuticals, as well as expanding applications in gene therapy and regenerative medicine. A vital recommendation is tapping into emerging markets, leveraging cost-efficient production technologies, and forming strategic partnerships for market expansion. However, market growth is challenged by factors such as high production costs, complex regulatory landscapes, and intellectual property issues. The technical complexities involved in protein expression and purification also pose hurdles. To drive innovation, research should focus on optimizing expression systems, developing novel stabilizing techniques for storage and transportation, and utilizing CRISPR-based technologies to enhance protein functionality. Insights suggest a competitive but rapidly evolving market, characterized by continuous technological advancements and a shift towards precision medicine. Companies need to stay abreast of technological trends and regulatory changes, emphasizing sustainability and ethical considerations in their business models to achieve long-term success in the recombinant protein market.

KEY MARKET STATISTICS
Base Year [2023] USD 5.05 billion
Estimated Year [2024] USD 5.80 billion
Forecast Year [2030] USD 13.04 billion
CAGR (%) 14.51%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Recombinant Proteins Market

The Recombinant Proteins Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising focus on personalized medicine & protein therapeutics in the consumers
    • High prevalence of infectious & chronic diseases among geriatric population and children
    • Surging inclination of demand toward biologics and biosimilars proteins
  • Market Restraints
    • Concerns regarding time consumption coupled with high costs & maintenance of recombinant protein
  • Market Opportunities
    • Increasing focus on biomarker discovery and surging investments recombinant protein development
    • Growing potential for recombinant protein in animal reproduction, feed efficiency, and health
  • Market Challenges
    • Availability of alternative products and several issues in production

Porter's Five Forces: A Strategic Tool for Navigating the Recombinant Proteins Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Recombinant Proteins Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Recombinant Proteins Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Recombinant Proteins Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Recombinant Proteins Market

A detailed market share analysis in the Recombinant Proteins Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Recombinant Proteins Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Recombinant Proteins Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Recombinant Proteins Market, highlighting leading vendors and their innovative profiles. These include Takara Bio Inc., GeoVax Labs, Inc., Takeda Pharmaceutical Company Limited, LenioBio GmbH, Sino Biological, Inc., Sanofi S.A., Bio-Rad Laboratories, Inc., R&D Systems, Inc. by Bio-Techne Corporation, Proteos, Inc., BPS Bioscience, Inc., Proteintech Group, Inc., BioLegend, Inc. by PerkinElmer, Inc., Thermo Fisher Scientific, Inc., Miltenyi Biotec B.V. & Co. KG, Fortis Life Sciences LLC, Sartorius AG, Bristol-Myers Squibb Company, Creative BioMart Inc., Biogen Inc., Abnova Corporation, Hzymes Biotech, Merck KGaA, Novartis AG, Agilent Technologies, Inc., Lonza Group AG, SK bioscience, Eli Lilly and Company, Johnson & Johnson Services, Inc., Bhat Bio-tech India Private Limited, GenScript Biotech Corporation, Marin Biologic Laboratories, Inc., Meridian Bioscience, Inc. by SD Biosensor Inc., ProMab Biotechnologies, Inc., Abcam PLC, Laurus Labs Limited, Biologics International Corp, Croyez Bioscience Co., Ltd., Enzo Life Sciences, Inc., and Selvita S.A..

Market Segmentation & Coverage

This research report categorizes the Recombinant Proteins Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Adhesion Molecules & Receptors, Growth Factors & Chemokines, Immune Response Proteins, Kinase Proteins, Membrane Proteins, Recombinant Metabolic Enzymes, Regulatory Proteins, and Structural Proteins.
  • Based on Services, market is studied across Cloning, Expression, and Purification.
  • Based on End-User, market is studied across Academic Research Institutes, Contract Research Organizations & Contract Manufacturing Organizations, and Pharmaceutical & Biopharmaceutical Companies.
  • Based on Function, market is studied across Diagnostics and Drug Discovery & Development. The Drug Discovery & Development is further studied across Biologics, Cell & Gene Therapy, and Vaccines.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising focus on personalized medicine & protein therapeutics in the consumers
      • 5.1.1.2. High prevalence of infectious & chronic diseases among geriatric population and children
      • 5.1.1.3. Surging inclination of demand toward biologics and biosimilars proteins
    • 5.1.2. Restraints
      • 5.1.2.1. Concerns regarding time consumption coupled with high costs & maintenance of recombinant protein
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing focus on biomarker discovery and surging investments recombinant protein development
      • 5.1.3.2. Growing potential for recombinant protein in animal reproduction, feed efficiency, and health
    • 5.1.4. Challenges
      • 5.1.4.1. Availability of alternative products and several issues in production
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Significant use of adhesion molecules & receptors for research purposes
    • 5.2.2. Services: Expression services focus on high yields and compatibility with target protein characteristics
    • 5.2.3. End-User: Extensive utilization of recombinant proteins in pharmaceutical and biopharmaceutical companies
    • 5.2.4. Function: Potential demand of recombinant proteins for drug discovery & development
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Recombinant Proteins Market, by Product

  • 6.1. Introduction
  • 6.2. Adhesion Molecules & Receptors
  • 6.3. Growth Factors & Chemokines
  • 6.4. Immune Response Proteins
  • 6.5. Kinase Proteins
  • 6.6. Membrane Proteins
  • 6.7. Recombinant Metabolic Enzymes
  • 6.8. Regulatory Proteins
  • 6.9. Structural Proteins

7. Recombinant Proteins Market, by Services

  • 7.1. Introduction
  • 7.2. Cloning
  • 7.3. Expression
  • 7.4. Purification

8. Recombinant Proteins Market, by End-User

  • 8.1. Introduction
  • 8.2. Academic Research Institutes
  • 8.3. Contract Research Organizations & Contract Manufacturing Organizations
  • 8.4. Pharmaceutical & Biopharmaceutical Companies

9. Recombinant Proteins Market, by Function

  • 9.1. Introduction
  • 9.2. Diagnostics
  • 9.3. Drug Discovery & Development
    • 9.3.1. Biologics
    • 9.3.2. Cell & Gene Therapy
    • 9.3.3. Vaccines

10. Americas Recombinant Proteins Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Recombinant Proteins Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Recombinant Proteins Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. iTolerance and Northway Biotech Form Manufacturing Pact for Fusion Protein
    • 13.3.2. Biovian Invests Over EUR 50M in Manufacturing Facility in Finland
    • 13.3.3. Fortis Life Sciences acquires International Point of Care
    • 13.3.4. Curia Expands Cell Line Development Offering with CHOZN Platform
    • 13.3.5. Future Fields raises USD 11.2 million to scale up fruit flies for recombinant protein production
    • 13.3.6. Merck's Biodevelopment Centre Expansion, Martillac, France
    • 13.3.7. Shenandoah Biotechnology Introduces Expanded Range of CTGrade Recombinant Proteins Manufactured Following cGMP Practices
    • 13.3.8. Fujifilm to Acquire Shenandoah Biotechnology, Leading Manufacturer of Recombinant Proteins
    • 13.3.9. Thermo Fisher Scientific Completes Acquisition of PeproTech, engaged in Recombinant Proteins

Companies Mentioned

  • 1. Takara Bio Inc.
  • 2. GeoVax Labs, Inc.
  • 3. Takeda Pharmaceutical Company Limited
  • 4. LenioBio GmbH
  • 5. Sino Biological, Inc.
  • 6. Sanofi S.A.
  • 7. Bio-Rad Laboratories, Inc.
  • 8. R&D Systems, Inc. by Bio-Techne Corporation
  • 9. Proteos, Inc.
  • 10. BPS Bioscience, Inc.
  • 11. Proteintech Group, Inc.
  • 12. BioLegend, Inc. by PerkinElmer, Inc.
  • 13. Thermo Fisher Scientific, Inc.
  • 14. Miltenyi Biotec B.V. & Co. KG
  • 15. Fortis Life Sciences LLC
  • 16. Sartorius AG
  • 17. Bristol-Myers Squibb Company
  • 18. Creative BioMart Inc.
  • 19. Biogen Inc.
  • 20. Abnova Corporation
  • 21. Hzymes Biotech
  • 22. Merck KGaA
  • 23. Novartis AG
  • 24. Agilent Technologies, Inc.
  • 25. Lonza Group AG
  • 26. SK bioscience
  • 27. Eli Lilly and Company
  • 28. Johnson & Johnson Services, Inc.
  • 29. Bhat Bio-tech India Private Limited
  • 30. GenScript Biotech Corporation
  • 31. Marin Biologic Laboratories, Inc.
  • 32. Meridian Bioscience, Inc. by SD Biosensor Inc.
  • 33. ProMab Biotechnologies, Inc.
  • 34. Abcam PLC
  • 35. Laurus Labs Limited
  • 36. Biologics International Corp
  • 37. Croyez Bioscience Co., Ltd.
  • 38. Enzo Life Sciences, Inc.
  • 39. Selvita S.A.

LIST OF FIGURES

  • FIGURE 1. RECOMBINANT PROTEINS MARKET RESEARCH PROCESS
  • FIGURE 2. RECOMBINANT PROTEINS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. RECOMBINANT PROTEINS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. RECOMBINANT PROTEINS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. RECOMBINANT PROTEINS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. RECOMBINANT PROTEINS MARKET DYNAMICS
  • TABLE 7. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY ADHESION MOLECULES & RECEPTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY GROWTH FACTORS & CHEMOKINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY IMMUNE RESPONSE PROTEINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY KINASE PROTEINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY MEMBRANE PROTEINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY RECOMBINANT METABOLIC ENZYMES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY REGULATORY PROTEINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY STRUCTURAL PROTEINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY CLONING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY EXPRESSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PURIFICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS & CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY CELL & GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 83. INDIA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 88. INDONESIA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 93. JAPAN RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 98. MALAYSIA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 103. PHILIPPINES RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 108. SINGAPORE RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 113. SOUTH KOREA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 118. TAIWAN RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 123. THAILAND RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 128. VIETNAM RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 139. DENMARK RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 144. EGYPT RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 149. FINLAND RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 154. FRANCE RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 159. GERMANY RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 164. ISRAEL RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 169. ITALY RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 174. NETHERLANDS RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 179. NIGERIA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 184. NORWAY RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 189. POLAND RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 194. QATAR RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 199. RUSSIA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 204. SAUDI ARABIA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 214. SPAIN RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 219. SWEDEN RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 224. SWITZERLAND RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 229. TURKEY RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED ARAB EMIRATES RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 240. RECOMBINANT PROTEINS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 241. RECOMBINANT PROTEINS MARKET, FPNV POSITIONING MATRIX, 2023